Slide 1: Q4 Report October – December 2024
Q4 Report October – December 2024 Stockholm, February 13, 2025 BioArctic AB
Slide 2: Presenting team
Presenting team GUNILLA OSSWALD, ANDERS MARTIN-LÖF, IR contact: CEO CFO Oskar Bosson, VP Communications & IR +46 704 10 71 80 ir@bioarctic.se Next Report: 2025 Q1 Report May 21, 2025 To subscribe to financial reports/press releases and for more information, please visit www.bioarctic.com 2 BioArctic
Slide 3: Disclaimer
Disclaimer • This presentation has been prepared and produced by BioArctic AB (publ) (“BioArctic”) solely for the benefit of investment analysis of BioArctic and may not be used for any other purpose. Unless otherwise stated, BioArctic is the source for all data contained in this presentation. Such
Slide 4: Q4 highlights – the beginning of a new era for BioArctic
Q4 highlights – the beginning of a new era for BioArctic First license Exidavnemab Leqembi® royalty agreement including phase 2a in and treated patients BrainTransporter Parkinson’s disease continue to grow signed with BMS started 4 BioArctic AB
Slide 5: BioArctic – a global pioneer in neurodegenerative diseases
BioArctic – a global pioneer in neurodegenerative diseases Focus on neurodegenerative disorders Highly selective antibodies targeting aggregated forms of toxic proteins • Disorders with very large unmet needs and large patient populations World-class R&D organization leveraging strong collaborations
Slide 6: License agreement with BMS opens up a broad possibility for new partnerships
License agreement with BMS opens up a broad possibility for new partnerships and sets the stage for a new era for BioArctic Global license for BioArctic’s pyroglutamate-Amyloid Beta antibody program • BAN1503 and BAN2803 which includes BrainTransporter technology Subject to approval under Hart-Scott
Slide 7: Strong new data validating the BrainTransporter platform
Strong new data validating the BrainTransporter platform presented according to plan, and has generated large interest BioArctic BrainTransporter • Validation data demonstrate rapid, broad and deep brain distribution by BT • Versatile platform which can be used across modalities • Seen a lot of exte
Slide 8: Phase 2a study with exidavnemab on track
Phase 2a study with exidavnemab on track Exidavnemab • Phase 2a ongoing in Parkinson’s disease, exploring to also include patients with Multiple System Atrophy • Low dose part fully recruited • Expected readout H1 2026, with interim safety review Q3 2025 • Offers opportunities in several neuronal sy
Slide 9: Number of patients treated with Leqembi continues to expand
Number of patients treated with Leqembi continues to expand – over 20,000 patients now on treatment globally Regulatory • Now approved in 10 countries, Mexico and Macau added in January • Regulatory reviews ongoing in 17 markets and regions, incl. EU • EC has asked the CHMP to consider two additiona
Slide 10: Simplified diagnosis and continued development of Leqembi
Simplified diagnosis and continued development of Leqembi could increase patient population and convenience Approved File accepted (US) (10 geographies) Approved (US) PDUFA Aug 31, 2025 To be submitted Subcutaneous Subcutaneous Intravenous Intravenous Convenient autoinjector: autoinjector: treatment
Slide 11: A broad project portfolio with a focus on neurodegenerative diseases
A broad project portfolio with a focus on neurodegenerative diseases Regulatory Project m Partner Discovery Preclinical Phase 1 Phase 2 Phase 3 & Market ALZHEIMER’S DISEASE Lecanemab (BAN2401) (Clarity AD) Eisai1 Early Alzheimer’s disease2 Lecanemab (BAN2401) (AHEAD 3-45) Eisai1 Preclinical (asympto
Slide 12: Financial Summary
Financial Summary 12 BioArctic AB
Slide 13: Leqembi on track to reach FY 2024 forecast
Leqembi on track to reach FY 2024 forecast • Global sales Q4-24 were ¥ 13.3 B (~87 MUSD), 33% BioArctic royalty increase from Q3-24 − Royalties increased by 38% quarter of quarter to SEK 96.7 M 120 • US expansion in line with updated forecast − ¥ 7.7 B in Q4 (~50 MUSD), 31% growth from Q3 100 96,7 −
Slide 14: Operating loss of SEK 53 M in the fourth quarter
Operating loss of SEK 53 M in the fourth quarter Net Revenues (SEK M) OPEX by function (SEK M) Operating Profit/Loss (SEK M) 393 143 301 121 101 131 88 95 209 Other 77 101 G&A 50 -26 -53 3 11 30 -101 -78 -73 -76 M&S Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 R&D Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q4 Q1 Q2 Q3 Q4 2023 2024 2024 20
Slide 15: Growing royalties further strengthen the financial base
Growing royalties further strengthen the financial base Net Result (SEK M) Cash Flow From Operating Cash Balance (SEK M) Activities (SEK M) 294 301 1 106 1 112 125 1 042 998 991 890 126 804 779 -68 -20 -31 -102 -87 -58 -64 -53 -80 -27 -114 -94 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3
Slide 16: Upcoming news flow and closing remarks
Upcoming news flow and closing remarks 16 BioArctic AB
Slide 17: Upcoming news flow
Upcoming news flow Q1 2025 Q2 2025 Q3 2025 Q4 2025 Congresses AD/PD, Apr 1 - Apr 5 AAIC, Jul 27 - Jul 31 CTAD, Dec 1 - 4 Potential approval of Capital Markets Day, Potential US approval BMS agreement by June 2, Stockholm of lecanemab SC-AI US authorities and online maintenance dosing Potential US fi
Slide 18: In summary
In summary Leqembi royalty BrainTransporter Strong financial revenue and patient generating interest position – expect to numbers continue across the industry be profitable in 2025 to grow 18 BioArctic AB
Slide 19: BioArctic will, through world-leading innovative research, create drugs
” BioArctic will, through world-leading innovative research, create drugs that improve the lives of patients with neurodegenerative diseases. 19 BioArctic AB